SparingVision is a biotechnology company focused development of genomic medicines for the treatment of blinding inherited retinal diseases. Founded in 2016, SparingVision is backed by investors that include Bpifrance, Foundation Fighting Blindness, Ysios Capital, Jeito Capital, and 4BIO Capital and is headquartered in Paris.
FOUNDED:
2016
INDUSTRY:
Biotechnology, Life Science
You are seconds away from signing up for the hottest list in New York Tech!
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.
